Idiopathic Pulmonary Fibrosis – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of IPF for each country, as well as annualized case counts projected to the national population
Clarivate Epidemiology’s IPF forecast will answer the following questions:
- Of all people with IPF, how many in each country have been formally diagnosed?
- Of all people formally diagnosed with IPF, how many in each country have been drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of IPF over the forecast period?
- How many people diagnosed with IPF also have gastroesophageal reflux disease (GERD), pulmonary hypertension (PH), emphysema, and/or obstructive sleep apnea (OSA)?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following IPF patient populations:
- Diagnosed prevalent cases.
- Diagnosed incident cases.
- Diagnosed prevalent cases by stages.
- Drug-treated prevalent cases.
- Diagnosed prevalent cases with comorbid GERD.
- Diagnosed prevalent cases with comorbid PH.
- Diagnosed prevalent cases with comorbid emphysema.
- Diagnosed prevalent cases with comorbid OSA.
Note: Coverage may vary by country.
